Wheler J - Search Results

1

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.

Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. Said R, et al. Among authors: wheler j. Ann Oncol. 2014 Jan;25(1):276-82. doi: 10.1093/annonc/mdt524. Ann Oncol. 2014. PMID: 24356639 Free PMC article.

2

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.

Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Wheler JJ, et al. Ann Oncol. 2012 Aug;23(8):1963-1967. doi: 10.1093/annonc/mds027. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377564 Free PMC article.

3

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Naing A, et al. Among authors: wheler jj. Ann Oncol. 2012 Nov;23(11):2960-2963. doi: 10.1093/annonc/mds130. Epub 2012 Jun 27. Ann Oncol. 2012. PMID: 22745218 Free PMC article.

4

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Wheler JJ, et al. Ann Oncol. 2013 Mar;24(3):838-42. doi: 10.1093/annonc/mds524. Epub 2012 Nov 8. Ann Oncol. 2013. PMID: 23139256 Free PMC article.

5

Body composition and survival in the early clinical trials setting.

Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Veasey Rodrigues H, et al. Among authors: wheler jj. Eur J Cancer. 2013 Oct;49(15):3068-75. doi: 10.1016/j.ejca.2013.06.026. Epub 2013 Jul 15. Eur J Cancer. 2013. PMID: 23867127

6

Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.

Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Janku F, et al. Among authors: wheler jj. Ann Oncol. 2017 Mar 1;28(3):642-650. doi: 10.1093/annonc/mdw670. Ann Oncol. 2017. PMID: 27993791 Free PMC article.

7

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Henary H, et al. Among authors: wheler j. Ann Oncol. 2013 Aug;24(8):2158-65. doi: 10.1093/annonc/mdt115. Epub 2013 Apr 10. Ann Oncol. 2013. PMID: 23576709 Free PMC article. Clinical Trial.

8

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Fu S, et al. Among authors: wheler j. Ann Oncol. 2015 May;26(5):1012-1018. doi: 10.1093/annonc/mdv066. Epub 2015 Feb 10. Ann Oncol. 2015. PMID: 25669829 Free PMC article. Clinical Trial.

9

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. Garrido-Laguna I, et al. Among authors: wheler jj. PLoS One. 2012;7(5):e38033. doi: 10.1371/journal.pone.0038033. Epub 2012 May 31. PLoS One. 2012. PMID: 22675430 Free PMC article.

10

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.

Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Falchook GS, et al. Among authors: wheler jj. Ann Oncol. 2013 Dec;24(12):3004-11. doi: 10.1093/annonc/mdt395. Epub 2013 Oct 24. Ann Oncol. 2013. PMID: 24158411 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters